Galapagos NV (GLPGF)

26.20 0.00 (0.00%) As of 11:48AM EDT. Market open.

Galapagos NV

Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
https://www.glpg.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,123

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Paulus A. Stoffels M.D., Ph.D.	CEO, Chairman, Interim Head of R&D	1.33M	N/A	1962
Mr. Thad Huston	Executive VP, CFO & COO	N/A	N/A	1971
Ms. Sofie Van Gijsel	Head of Investor Relations	N/A	N/A	N/A
Ms. Valeria Cnossen	Executive VP & General Counsel	N/A	N/A	1974
Marieke Vermeersch	Head of Corporate Communication	N/A	N/A	N/A
Ms. Annelies Missotten	Executive VP & Chief Human Resources Officer	N/A	N/A	1973
Ms. Ellen Van Der Aar	Head of Development	N/A	N/A	N/A
Mr. Philippe Alen M.B.A., Ph.D., Pharm.D.	Senior VP & Head of Business Development	N/A	N/A	N/A
Mr. Dirk De Naeyer	Head of Development Operations	N/A	N/A	N/A
Ms. Alice Dietrich	Head of Medical Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Corporate governance

Galapagos NV’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 7; Board: 4; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.